Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $0
- P/E (trailing)
- —
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- —
Trading
- Volume
- 5,000
- Avg volume
- —
- Day's range
- $0.10 – $0.10
- Shares out
- —
- Stochastic %K
- 65%
- Beta
- —
- Analysts
- —
- Price target
- —
Company profile
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, engages in developing immunotherapy for cancer in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome; and phase 2 for the treatment of influenza. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; and AI program, a nov...
Show more
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, engages in developing immunotherapy for cancer in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome; and phase 2 for the treatment of influenza. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; and AI program, a novel drug discovery therapies for the treatment of influenza and respiratory syncytial viruses. Poolbeg Pharma plc was incorporated in 2021 and is based in London, United Kingdom.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 44 20 7183 1499
- Website
- https://www.poolbegpharma.com
- Address
- The Clubhouse Holborn, 20 St. Andrew Street, London, United Kingdom
Latest news
No headlines yet.
